Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2

Journal of Immunotherapy

Volumn 29, Issue 2, 2006, Pages 208-214

  Attia, Peter ^a   Powell Jr , Daniel J ^a   Maker, Ajay V ^a   Kreitman, Robert J ^a   Pastan, Ira ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD25; Depletion; Human; Immunotoxin; LMB 2; Pseudomonas exotoxin; Regulatory T cell

Indexed keywords

BASILIXIMAB; CANCER VACCINE; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR ALPHA; PSEUDOMONAS EXOTOXIN; TRANSCRIPTION FACTOR FOXP3;

ACTIVE IMMUNIZATION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COMPARTMENTALIZATION; CYTOKINE RELEASE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TARGET CELL; TUMOR MODEL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CANCER VACCINES; CELL DEATH; CELLS, CULTURED; EXOTOXINS; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LYMPHOCYTE DEPLETION; MICE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 33646366039     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000187959.45803.0c     Document Type: Article

References (34)

1. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
2. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345-352.
3. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20-21.
4. Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother. 2003;26:85-93.
5. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107-118.
6. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444-1453.
7. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
8. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569-580.
9. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
10. Kreitman RJ. Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opin Biol Ther. 2004;4:1115-1128.
11. Chaudhary VK, Queen C, Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394-397.
12. Kreitman RJ, Batra JK, Seetharam S, et al. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem. 1993;4:112-120.
13. Kreitman RJ, Bailon P, Chaudhary VK, et al. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 1994;83:426-434.
14. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 1999;94:3340-3348.
15. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636.
16. Kreitman RJ, Pastan I. Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. Bioconjug Chem. 1993;4:581-585.
17. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
18. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol. 1999;163:1690-1695.
19. Powell DJ Jr, Parker LL, Rosenberg SA. Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples. J Immunother. 2005;28:403-411.
20. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701-1712.
21. Waldmann TA, Goldman CK, Bongiovanni KF, et al. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood. 1988;72:1805-1816.
22. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28:120-128.
23. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
24. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
25. Jones E, Golgher D, Simon AK, et al. The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice. Novartis Found Symp. 2004;256:149-152.
26. Hu HM, Poehlein CH, Urba WJ, et al. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002;62:3914-3919.
27. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281-287.
28. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther. 2003;5:44-51.
29. Waters CA, Schimke PA, Snider CE, et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol. 1990;20:785-791.
30. Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denilukin Diftitox, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005.
31. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74:961-965.
32. Walz G, Zanker B, Murphy JR, et al. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells. Transplantation. 1990;49:198-201.
33. Walz G, Zanker B, Brand K, et al. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci USA. 1989;86:9485-9488.
34. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc. 1998;30:2155-2158.